Cipla reported results for the fourth quarter and year ended March 31, 2013.
The company has reported a fall of 8.29% in its net profit at Rs 267.56 crore in Q4FY13 as compared to net profit of Rs 291.74 crore in the same quarter previous year. However, total income of the company has increased by 6.33% to Rs 2025.14 crore as compared to Rs 1904.54 crore in corresponding quarter last year.
For the year ended March 31, 2013, the company has registered 34.09% rise in its net profit at Rs 1507.11 crore in FY13 as against Rs 1123.96 crore in previous years. Total income of the company has increased to Rs 8431.55 crore as compared to Rs 7125.80 crore in FY12, up by 18.31%.
On consolidated basis, for the full year ended March 31, 2013, the company has posted a 35.01% rise in its net profit at Rs 1544.85 crore under year under review as compared to Rs 1144.24 crore in FY12. Total income has increased by 18.73% at Rs 8501.47 crore for year under review as compared to Rs 7160.23 crore for the period ended March 31, 2012.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: